CA2626698C - Method of treating clostridium difficile-associated diarrhea - Google Patents

Method of treating clostridium difficile-associated diarrhea Download PDF

Info

Publication number
CA2626698C
CA2626698C CA2626698A CA2626698A CA2626698C CA 2626698 C CA2626698 C CA 2626698C CA 2626698 A CA2626698 A CA 2626698A CA 2626698 A CA2626698 A CA 2626698A CA 2626698 C CA2626698 C CA 2626698C
Authority
CA
Canada
Prior art keywords
composition
mcc
use according
weight
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2626698A
Other languages
English (en)
French (fr)
Other versions
CA2626698A1 (en
Inventor
Pamela Sears
Youe-Kong Shue
Starr Louise Miller-Shangle
Robert Brian Walsh
Farah Babakhani
Yu-Hung Chiu
Alex Romero
Sherwood Gorbach
Thomas John Louie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of CA2626698A1 publication Critical patent/CA2626698A1/en
Application granted granted Critical
Publication of CA2626698C publication Critical patent/CA2626698C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2626698A 2005-10-21 2006-10-23 Method of treating clostridium difficile-associated diarrhea Expired - Fee Related CA2626698C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72913505P 2005-10-21 2005-10-21
US60/729,135 2005-10-21
US74964105P 2005-12-12 2005-12-12
US60/749,641 2005-12-12
PCT/US2006/041436 WO2007048059A2 (en) 2005-10-21 2006-10-23 Method of treating clostridium difficile-associated diarrhea

Publications (2)

Publication Number Publication Date
CA2626698A1 CA2626698A1 (en) 2007-04-26
CA2626698C true CA2626698C (en) 2015-12-01

Family

ID=37963388

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2626698A Expired - Fee Related CA2626698C (en) 2005-10-21 2006-10-23 Method of treating clostridium difficile-associated diarrhea

Country Status (7)

Country Link
EP (1) EP1940417A4 (https=)
JP (1) JP2009512691A (https=)
KR (1) KR101399621B1 (https=)
CN (2) CN101340919B (https=)
AU (1) AU2006304868B2 (https=)
CA (1) CA2626698C (https=)
WO (1) WO2007048059A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
CN104846044B (zh) * 2014-02-17 2019-02-01 上海医药工业研究院 一种提高非达霉素产量的发酵培养基
CN105237599B (zh) * 2015-10-09 2018-10-02 华北制药集团新药研究开发有限责任公司 闰年霉素a4晶体及其制备方法
CN107970253B (zh) * 2017-10-25 2020-05-26 中山大学 台勾霉素衍生物在制备治疗寨卡病毒感染引起的相关疾病和/或症状的药物中的应用
CN107714713B (zh) * 2017-10-25 2020-05-26 中山大学 台勾霉素衍生物在制备治疗登革病毒感染引起的相关疾病和/或症状的药物中的应用
EP3801578B1 (en) * 2018-06-07 2023-08-30 Artugen Therapeutics Ltd. B. amyloliquefaciens strain and therapeutic use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
AU2003251902B2 (en) * 2002-07-29 2008-03-06 Merck Sharp & Dohme Llc Tiacumicin production
ATE516024T1 (de) * 2004-05-14 2011-07-15 Optimer Pharmaceuticals Inc Behandlung von krankheiten im zusammenhang mit der anwendung von antibiotika
JP5166040B2 (ja) * 2005-01-31 2013-03-21 オプティマー ファーマシューティカルズ、インコーポレイテッド １８員大環状化合物及びその類似化合物

Also Published As

Publication number Publication date
CA2626698A1 (en) 2007-04-26
CN101340919A (zh) 2009-01-07
CN102503994A (zh) 2012-06-20
KR20080064177A (ko) 2008-07-08
AU2006304868A1 (en) 2007-04-26
CN101340919B (zh) 2011-12-07
KR101399621B1 (ko) 2014-06-18
HK1126410A1 (en) 2009-09-04
EP1940417A4 (en) 2010-07-07
WO2007048059A3 (en) 2007-05-31
WO2007048059A2 (en) 2007-04-26
JP2009512691A (ja) 2009-03-26
AU2006304868B2 (en) 2013-02-21
EP1940417A2 (en) 2008-07-09

Similar Documents

Publication Publication Date Title
US20140107054A1 (en) Method of treating clostridium difficile-associated diarrhea
AU2009308180B2 (en) Methods for treating gastrointestinal diseases
US20130274175A1 (en) Treatment of disease associated with the use of antibiotics
CA2626698C (en) Method of treating clostridium difficile-associated diarrhea
Citron et al. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection
Raasch Anidulafungin: review of a new echinocandin antifungal agent
Naber et al. Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections
Bäckström et al. Effect of ceftobiprole on the normal human intestinal microflora
Yanagihara et al. Susceptibility of Clostridium species isolated in Japan to fidaxomicin and its major metabolite OP-1118
WO2012050826A1 (en) Methods for treating clostridium difficile infections
US7981859B2 (en) Glycopeptide composition with improved antibiotic activity
HK1126410B (en) Method of treating clostridium difficile-associated diarrhea
Katara et al. Role of bacteria and fungi in antibiotic production
CN120154605B (zh) 去氢钩藤碱在制备降低多黏菌素毒性药物中的应用
Aleem et al. Drugs in therapeutic application of dogs and cats
CN111249296B (zh) 一种抗真菌的药物组合物及互动抗真菌活性测定方法
Laughlin Harnessing Microbial Interactions to Elicit the Production of Polyene Macrolides in Streptomyces
Ortega et al. Activity of telithromycin against erythromycin-susceptible and-resistant Streptococcus pneumoniae isolates from adults with invasive infections
HK1075401A (en) A teicoplanin composition with improved antibiotic activity
JP2016069333A (ja) 新規化合物、その製造方法、及びその用途、並びに、新規微生物

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20171023